OTLC.OQBOncotelic Therapeutics, INC
10-Q: Oncotelic Q3: JV Progress Amidst Going Concern Warning
Sentiment:
Quarterly Report
Oncotelic Therapeutics reports a reduced net loss for Q3 2025, driven by the absence of goodwill impairment, while its GMP Bio joint venture advances drug pipeline and targets a 2026 Hong Kong IPO.
Delay expectedThe binding term sheet with Mosaic ImmunoEngineering, Inc. was mutually agreed to be extended to the end of 2025 to allow both companies to complete due diligence and finalize definitive agreements.
Capital raiseEntered into an Equity Purchase Agreement with Mast Hill Fund LP in August 2025, allowing the company to sell up to $25 million in common stock, contingent on an S-1 registration statement becoming effective.Issued a $560,000 secured convertible note to Mast Hill in July 2025, along with 2,000,000 warrants and 2,250,000 common shares as a commitment fee.Obtained additional short-term funding of $435,000 from Autotelic Inc. (a related party) during the nine months ended September 30, 2025, bringing the total outstanding to approximately $2.5 million.Received additional short-term funding of $10,000 from the CFO during the nine months ended September 30, 2025, with approximately $86,000 outstanding.Has $50,000 outstanding as a short-term loan from the CEO.
Worse than expectedWhile net loss decreased, this was primarily due to the absence of a $3.2 million goodwill impairment charge recorded in the prior year, masking underlying operational challenges.General and administrative expenses significantly increased by $0.3 million for the nine months ended September 30, 2025, indicating rising operational costs.The company continues to operate with a substantial accumulated deficit of $39.1 million and negative working capital of $18.5 million.Management explicitly states 'substantial doubt about the Company's ability to continue as a going concern' for the next year, highlighting severe financial instability.
Summary
- Net loss for the nine months ended September 30, 2025, was $1,068,225, a significant improvement from the $3,922,998 net loss for the same period in 2024, primarily due to no goodwill impairment in 2025.
- Cash and restricted cash increased to $429,000 as of September 30, 2025, from $106,128 at the beginning of the period.
- The company continues to face substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $39.1 million and negative working capital of $18.5 million as of September 30, 2025.
- General and administrative expenses increased by approximately $0.3 million for the nine months ended September 30, 2025, compared to the same period in 2024, largely due to higher stock-based compensation and operational costs.
- The joint venture (GMP Bio), in which the company holds a 45% ownership, completed a Phase 1 clinical trial for OT-101 in combination with IL-2 for advanced solid tumors, showing a tolerable safety profile.
- GMP Bio's drug pipeline was preliminarily estimated by Frost & Sullivan (Hong Kong) to have a potential value of approximately $1.7 billion, though this is non-binding and not a U.S. GAAP fair value.
- The JV is developing a nanoparticle platform, has completed formulation for everolimus for injection (with global clinical trials initiated), and plans IND filings for palbociclib, docetaxel, and paclitaxel in late 2025 or early 2026.
- A GMP manufacturing facility in San Diego received a Drug Manufacturing License in late 2024.
- The company entered into an Equity Purchase Agreement with Mast Hill Fund LP for up to $25 million in common stock, contingent on a registration statement becoming effective.
- Short-term loans from related parties, including Autotelic Inc., the CFO, and CEO, totaled approximately $2.87 million as of September 30, 2025.
- A litigation with a former employee was settled in October 2025 for $162,500, paid by Autotelic Inc. on the company's behalf.
Sentiment
Score: 3
Explanation: The company faces severe financial challenges, including a going concern warning, significant accumulated deficit, and negative working capital. While there are positive developments in the JV's pipeline and financing efforts, the fundamental financial stability remains highly precarious, indicating a high-risk profile.
Positives
- Net loss significantly decreased to $1.07 million for the nine months ended September 30, 2025, from $3.92 million in the prior year, primarily due to the absence of a $3.2 million goodwill impairment charge.
- Cash and restricted cash increased to $429,000 as of September 30, 2025, from $106,128 at December 31, 2024.
- The GMP Bio joint venture completed a Phase 1 clinical trial for OT-101 in combination with IL-2, demonstrating a tolerable safety profile.
- GMP Bio's drug pipeline received a preliminary, non-binding valuation of approximately $1.7 billion from Frost & Sullivan (Hong Kong).
- The JV is actively developing a nanoparticle platform with multiple product candidates, including everolimus for injection (global clinical trials initiated) and plans for IND filings for palbociclib, docetaxel, and paclitaxel.
- GMP Bio's San Diego manufacturing facility obtained a Drug Manufacturing License in late 2024.
- Secured an Equity Purchase Agreement with Mast Hill Fund LP for up to $25 million, providing a potential source of future capital.
- Cash provided by financing activities increased to $923,000 for the nine months ended September 30, 2025, from $615,000 in the prior year.
Negatives
- The company has an accumulated deficit of $39.1 million as of September 30, 2025, and a negative working capital of $18.5 million.
- Management has identified substantial doubt about the company's ability to continue as a going concern for the next year.
- Operating loss for the nine months ended September 30, 2025, was $658,039, compared to $344,559 (excluding goodwill impairment) in the prior year, indicating a deterioration in core operational performance.
- General and administrative expenses increased significantly by $0.3 million for the nine months ended September 30, 2025, compared to the same period in 2024.
- The company is in default on the Forever Prosperity Notes (formerly GMP Notes) totaling approximately $4.9 million as of September 30, 2025.
- Material weaknesses in internal control over financial reporting were identified, including a lack of formal policies, a functioning audit committee, segregation of duties, and qualified accounting personnel.
- Reliance on debt and equity financing to fund operations, with no assurance that such financing will be available on favorable terms or at all.
Risks
- Ability to successfully commercialize products and services on a large enough scale to generate profitable operations.
- Ability to maintain and develop relationships with customers and suppliers.
- Ability to successfully integrate acquired businesses or new products, or to realize anticipated synergies.
- Ability to raise additional funding and to continue as a going concern.
- Ability to successfully implement the business plan.
- The preliminary $1.7 billion valuation of GMP Bio's pipeline is non-binding, forward-looking, and based on assumptions, with no guarantee of actual fair value.
- Ability to avoid or adequately address intellectual property claims brought by third parties.
- Anticipated impact of any changes in industry regulation.
- Building and success of the nanoparticle platform and related product launches.
- Success of the DAO infrastructure company (Pet2DAO) and plans surrounding pet and animal health.
- Ability to register Pet2DAO tokens with the SEC and their potential tradability or value.
- The planned Hong Kong public offering for the JV is subject to numerous risks and uncertainties, with no assurance it will take place or at what valuation.
Future Outlook
The company's joint venture, GMP Bio, plans to conduct an initial public offering on the Hong Kong Stock Exchange in late 2026, with a potential enterprise valuation significantly exceeding $2 billion. The JV intends to advance OT-101 into Phase 2 and 3 clinical trials for high-grade glioma and pancreatic cancer, and to initiate clinical trials for new nanoparticle-formulated compounds (palbociclib, docetaxel, paclitaxel) in late 2025 or early 2026. The company also plans to independently develop OT-101 for animal health indications, potentially utilizing blockchain technologies, and will continue efforts to raise capital through equity and/or debt financing.
Management Comments
- Management expects to continue to incur significantly lower direct costs and losses in the foreseeable future, as a majority of the costs related with the development of OT-101 have been, and will be, incurred by the JV.
- Management recognizes the need to raise capital to remain viable as well as have the ability to develop its own products and achieve some of the plans to enhance shareholder value.
- Management believes that the potential equity and debt financing or other potential financing will provide the necessary funding for the Company to continue as a going concern, though cannot guarantee availability on favorable terms or at all.
- Management intends to re-evaluate the carrying value of the minority interest in GMP Bio in the coming quarter, given the JV's advances and planned public offering.
Industry Context
The company operates in the highly capital-intensive biotechnology industry, focusing on immuno-oncology and nanoparticle drug delivery, which are areas of significant innovation and investment. Its strategy of leveraging a joint venture (GMP Bio) to fund core drug development (OT-101) while exploring new platforms like nanoparticles and digital assets for animal health reflects a diversified approach common among smaller biotechs seeking to de-risk and maximize asset value. The planned Hong Kong IPO for GMP Bio aligns with a trend of biotechs seeking international capital markets for growth, especially given the high valuation estimates for novel drug pipelines.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | NA | Vuong Trieu, Ph.D. | 2025-11-17 | Granted up to 24,387.516 shares of Series A Convertible Preferred Stock as incentive compensation for capital raising and achievement of corporate milestones. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Material Weaknesses Identified | Identified material weaknesses in internal control over financial reporting, including lack of formal policies, functioning audit committee, segregation of duties, dedicated resources, qualified accounting personnel, and risk assessment procedures. | 2025-09-30 | Raises reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. |
Legal Proceedings
- Settled litigation with a former employee for breach of employment contract claim and counter claim in October 2025. Autotelic Inc. paid $162,500 on behalf of the company for full and final settlement, with neither party admitting wrongdoing.
Related Party Transactions
- Autotelic Inc. (partly-owned by CEO) provided $435,000 in additional short-term funding during the nine months ended September 30, 2025, with approximately $2.5 million outstanding.
- Autotelic Inc. paid $162,500 to a former employee on behalf of the company to settle litigation in October 2025, recorded as a debt from Autotelic.
- The CFO provided additional short-term funding of $10,000 during the nine months ended September 30, 2025, with approximately $86,000 outstanding.
- The CEO provided a short-term loan of $50,000, which remains outstanding.
- Dr. Vuong Trieu (CEO) was granted up to 24,387.516 shares of Series A Convertible Preferred Stock as incentive compensation, contingent on corporate milestones.
Stakeholder Impact
- Shareholders face significant dilution risk from ongoing equity financing and convertible debt conversions, but also potential upside from the GMP Bio JV's high valuation estimates and planned IPO.
- Employees may face uncertainty due to the company's going concern warning and reliance on external funding.
- Creditors, particularly holders of the Forever Prosperity Notes, face default risk, although the related party has not called for repayment.
- Customers and suppliers may experience reduced confidence due to the company's financial instability and internal control weaknesses.
Next Steps
- Advance OT-101 plus IL-2 into further clinical studies, exploring synergies with checkpoint inhibitors.
- Continue sponsoring investigator-initiated clinical studies for OT-101 in other oncology applications (lung cancer, pancreatic cancer).
- Complete formulation development work for three additional nanoparticle products in 2025 and initiate clinical trials for various compounds.
- File the investigational new drug (IND) and initiate Phase 1 trials for palbociclib, docetaxel, and paclitaxel in late 2025 or early 2026.
- File a registration statement on Form S-1 with the SEC for the Mast Hill Equity Purchase Agreement as soon as possible.
- GMP Bio plans to conduct an initial public offering on the Hong Kong Stock Exchange in late 2026.
- Continue to search for, evaluate, and recruit qualified independent outside directors.
- Hire qualified accounting personnel to prepare and report financial information in accordance with GAAP.
- Identify gaps in skills base and expertise of staff required to meet public company financial reporting requirements.
- Continue to develop policies and procedures on internal control over financial reporting and monitor effectiveness.
Key Dates
| Date | Description |
|---|---|
| 2019-04-30 | Company completed reverse merger with Oncotelic Inc. and entered into a Securities Purchase Agreement (Bridge SPA) with CEO and Bridge Investor. |
| 2019-08-01 | Company entered into Convertible Note Tranche #2 with the Bridge Investor. |
| 2019-11-30 | Company completed merger with PointR Data Inc (PointR Merger). |
| 2019-12-01 | Company closed its Fall 2019 Debt Financing, raising an additional $500,000. |
| 2020-06-30 | Company secured $2 million in debt financing (GMP Note) from GMP to conduct a clinical trial for OT-101 against COVID-19. |
| 2021-05-03 | Company entered into an Equity Purchase Agreement (EPL) and Registration Rights Agreement with Peak One Opportunity Fund, L.P. |
| 2021-08-01 | Company entered into Note Purchase Agreements with Autotelic, CFO, and accredited investors (August 2021 Notes). |
| 2021-09-30 | Company secured a further $1.5 million in debt financing (GMP Note 2) from GMP. |
| 2021-10-31 | Company entered into an Unsecured Convertible Note Purchase Agreement (October Purchase Agreement) with GMP for $0.5 million. |
| 2022-01-31 | Company entered into an Unsecured Convertible Note Purchase Agreement (January Purchase Agreement) with GMP for $0.5 million. |
| 2022-03-31 | Company formalized a JV, GMP Bio, with Dragon and GMP; entered into a Securities Purchase Agreement with Fourth Man for $250,000 convertible note. |
| 2022-05-31 | Company entered into a Securities Purchase Agreement with Mast Hill Fund for $0.6 million convertible notes. |
| 2022-06-30 | Company entered into a Securities Purchase Agreement with Blue Lake Partners, LLC for $340,000 convertible notes. |
| 2022-11-30 | Company formed Pet2DAO LLC as a wholly owned subsidiary. |
| 2023-07-01 | Company entered into a series of subscription agreements with accredited investors for the PPM-2 Financing. |
| 2023-12-01 | Company received $50,000 from the CEO as a short-term loan. |
| 2024-01-31 | PPM-2 Financing fully converted JH Darbie PPM-1 notes into PPM-2 notes. |
| 2024-02-01 | Fourth Man partially converted $35,000 of debt into 500,000 shares of Common Stock. |
| 2024-04-01 | Company entered into a binding term sheet with Mosaic ImmunoEngineering, Inc. |
| 2024-04-15 | Company filed its 2024 Annual Report on Form 10-K with the SEC. |
| 2024-05-01 | Blue Lake converted the balance of their $531,000 debt into 7,605,760 shares of Common Stock. |
| 2024-08-01 | Mosaic and the Company mutually agreed to extend the Term Sheet to expire at the earlier of definitive agreements or December 31, 2024. |
| 2024-12-31 | GMP Bio changed its fiscal year to a calendar year; Term Sheet with Mosaic further extended to June 30, 2025. |
| 2025-01-01 | GMP manufacturing facility initiated in San Diego. |
| 2025-03-01 | Fourth Man partially converted approximately $68,000 of debt into 1,002,832 shares of Common Stock. |
| 2025-03-31 | JV successfully completed a Phase 1 clinical trial evaluating OT-101 in combination with IL-2. |
| 2025-04-21 | SEC made the post-effective amendment for the EPL effective. |
| 2025-04-29 | Company filed a prospectus under rule 424b3 with the SEC. |
| 2025-05-31 | GMP Bio and Golden Mountain Partners entered into a note purchase agreement for operating expenses. |
| 2025-07-31 | Company entered into a securities purchase agreement with Mast Hill for a $560,000 secured convertible note (July 2025 Mast Note); issued 2,250,000 shares of Common Stock as commitment shares to Mast Hill. |
| 2025-08-01 | Company entered into an Equity Purchase Agreement (Mast EPA) and Registration Rights Agreement with Mast Hill Fund LP; issued 20,322,930 restricted shares to Jefferson Capital Ventures, LLC and 4,064,586 shares to Valor Nation, Inc. for consulting services. |
| 2025-08-12 | Company filed a Current Report on Form 8-K regarding the Jefferson and Valor ICAs. |
| 2025-08-31 | Mast Hill partially converted approximately $264,000 of accrued interest into 3,860,000 shares of Common Stock. |
| 2025-09-01 | Fourth Man issued notice to convert approximately $44,000 of debt, resulting in an obligation to issue 656,082 shares of Common Stock. |
| 2025-09-30 | End of the quarterly reporting period. |
| 2025-10-01 | Autotelic paid $162,500 to a former employee on behalf of the company to settle litigation; Company partially converted approximately $44,000 of Fourth Man debt into 663,608 shares of Common Stock. |
| 2025-11-01 | Company partially converted approximately $45,000 of Fourth Man debt into 668,748 shares of Common Stock. |
| 2025-11-13 | Board approved a grant of 1,818,182 shares of Common Stock to Out the Box Capital, Inc. for marketing services. |
| 2025-11-17 | Company entered into a restricted stock agreement with Dr. Trieu (CEO) for up to 24,387.516 shares of Series A Convertible Preferred Stock upon achievement of milestones. |
Keywords
Biotechnology, Immuno-oncology, TGF-beta inhibitor, OT-101, Nanoparticle platform, Cancer therapeutics, SEC filing, 10-Q, Capital raise, Corporate governance, Clinical trials, Going concern, GMP Bio, Drug development
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.